Stoke Therapeutics (STOK) Current Assets (2018 - 2026)

Stoke Therapeutics has reported Current Assets for 9 years, with the latest figure at $366.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 2.41% year-over-year to $366.7 million; the trailing twelve-month figure through Mar 2026 stood at $366.7 million (down 2.41% YoY), and the FY2025 full-year result was $305.7 million, up 31.34% from the prior year.
• Current Assets for Q1 2026 stood at $366.7 million, up from $305.7 million in the prior quarter.
• The five-year high for Current Assets was $375.7 million in Q1 2025, with the low at $193.3 million in Q1 2024.
• Average Current Assets over 5 years is $272.5 million, with a median of $270.0 million recorded in 2025.
• Year-over-year, Current Assets dropped 28.48% in 2024 and jumped 94.4% in 2025.
• Tracing STOK's Current Assets over 5 years: stood at $244.1 million in 2022, then decreased by 11.77% to $215.3 million in 2023, then gained by 8.09% to $232.8 million in 2024, then jumped by 31.34% to $305.7 million in 2025, then rose by 19.95% to $366.7 million in 2026.
• The last three Current Assets figures came in at $366.7 million (Q1 2026), $305.7 million (Q4 2025), and $272.4 million (Q3 2025), per Business Quant data.

Peer Comparison